Physician profile
Samara D Harrell
NPI 1306285986
$2,508.82
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $708 · 2022: $730 · 2023: $761 · 2024: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.87 | 2021-2024 | |
| Lilly USA, LLC | $342.16 | 2021-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $206.38 | 2021-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $186.51 | 2021-2024 | Wegovy |
| Amgen INC. | $155.81 | 2023-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $120.18 | 2021-2024 | |
| Pfizer INC. | $117.05 | 2021-2024 | |
| Dexcom, INC. | $95.75 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $63.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.72 | 2021-2023 | Jardiance, Tradjenta |
| Nestle Healthcare Nutrition INC. | $49.19 | 2023 | |
| Abbott Laboratories | $48.22 | 2021-2022 | |
| Exact Sciences Corporation | $43.52 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $37.02 | 2022 | |
| Ironwood Pharmaceuticals, INC | $34.90 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.51 | 2023 | |
| Nevro Corp. | $26.44 | 2023 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $25.33 | 2022 | |
| Esperion Therapeutics, INC. | $25.13 | 2021 | |
| Aimmune Therapeutics, INC. | $22.57 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.83 | 2023 | Rexulti |
| Lundbeck LLC | $17.42 | 2024 | Rexulti |
| Genentech USA, INC. | $17.35 | 2021 | |
| Merck Sharp & Dohme LLC | $15.65 | 2024 | Verquvo |
| Medtronic, INC. | $15.43 | 2021 | |
| Glaxosmithkline, LLC. | $13.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samara Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.